Facing the facts: The indirect effects of cytomegalovirus

Transplantation

Volumn 84, Issue 6 SUPPL., 2007, Pages

  Emery, Vincent ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; VALACICLOVIR; VALGANCICLOVIR;

CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE CONTROL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 34748841976     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000280543.68747.67     Document Type: Conference Paper

References (29)

1. Emery VC, Cope AV, Bowen EF, et al. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190: 177.
2. Regoes RR, Bowen EF, Cope AV, et al. Modelling cytomegalovirus replication patterns in the human host: Factors important for pathogenesis. Proc Biol Sci 2006; 273: 1961.
3. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001; 54: 84.
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
5. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects (Abstract). J Exp Med 2005; 202: 673.
6. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031.
7. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
8. Kloover JS, Soots AP, Krogerus LA, et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000; 69: 2641.
9. Martelius T, Krogerus L, Hockerstedt K, et al. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 1998; 27: 996.
10. Martelius TJ, Blok MJ, Inkinen KA, et al. Cytomegalovirus infection, viral DNA, and immediate early-1 gene expression in rejecting rat liver allografts. Transplantation 2001; 71: 1257.
11. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
12. Fateh-Moghadam S, Bocksch W, Wessely R, et al. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003; 76: 1470.
13. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
14. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59: 496.
15. Kidd IM, Clark DA, Sabin CA, et al. Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000; 69: 2400.
16. Helentera I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior early graft function and survival. Geneva, Switzerland: 12th ESOT Congress, 15-19 October 2005 (Abstract PO-408).
17. Folkmane I, Bernarde K, Chapenko S, et al. Influence of early cytomegalovirus infection and acute graft rejection on chronic nephropathy development in renal transplant recipients. Geneva, Switzerland: 12th ESOT Congress, 15-19 October 2005 (Abstract PO-509).
18. Sola R, Diaz JM, Guirado L, et al. Significance of cytomegalovirus infection in renal transplantation. Transplant Proc 2003; 35: 1753.
19. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550.
20. Korzets A, Zevin D, Ori Y, et al. Elevated serum alkaline phosphatase levels in a renal transplant patient precede colitis. Transpl Infect Dis 2006; 8: 157.
21. Crespo MG, Arnal FM, Gomez M, et al. Cytomegalovirus colitis mimicking a colonic neoplasm or ischemic colitis 4 years after heart transplantation. Transplantation 1998; 66: 1562.
22. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: Etiology and management. Liver Transpl 2005; 11: 881.
23. Maurer JR. The spectrum of colonic complications in a lung transplant population. Ann Transplant 2000; 5: 54.
24. Korkmaz M, Kunefeci G, Selcuk H, et al. The role of early colonoscopy in CMV colitis of transplant recipients. Transplant Proc 2005; 37: 3059.
25. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100: 61.
26. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82: 398.
27. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
28. Ricart MJ, Malaise J, Moreno A, Crespo M, Fernandez-Cruz L. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005; 20: ii25.
29. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105.